Key clinical point: Patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) during their first complete remission (CR) from a mismatched unrelated donor (MMUD), umbilical cord blood (UCB), or a haploidentical-related donor (Haplo) had similar outcomes, making all of them a viable option in the absence of a matched related or unrelated donor.
Major finding: For patients who had transplants between 2015 and 2018, the 3-year overall survival of MMUD, UCB, and Haplo groups were 60%, 66%, and 63%, respectively ( P = .693). The rates of nonrelapse mortality ( P = .147), relapse ( P = .075), and graft-versus-host disease-free/relapse-free survival ( P = .365) were also similar between the 3 groups.
Study details: Findings are from a retrospective analysis of 1,932 patients with AML who underwent allo-HSCT during their first CR from MMUD, UCB or Haplo.
Disclosures: This study was supported by grants from the Practical Research Project for Allergic Diseases and Immunology from the Japan Agency for Medical Research and Development and the Aichi Cancer Research Foundation. The authors declared no conflicts of interest.
Source: Yanada M et al. Transplant Cell Ther. 2021 Sep 6. doi: 10.1016/j.jtct.2021.08.027 .